gene_symbol
HLA-DQB1
hgnc_id
HGNC:4944
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes neoantigen-specific T cells; CD8+ CTLs kill tumor cells presenting neoantigen peptides on HLA class I. HLA-DQB1 (class II) on APCs is used for CD4+ T-cell priming and is not a direct cytotoxic target.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Forms HLA-DQ with HLA-DQA1; presents peptides to CD4+ T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06751966
disease_id_num_tar_ref
5988
drug_id_num_tar_ref
16236